MedMira, Inc. : MedMira Invited to Attend Exclusive Conference on Military and Civilian Pre-Hospital Trauma Management
06/18/2012| 10:26am US/Eastern
Recommend:
Halifax, Nova Scotia, June 18, 2012 - MedMira Inc.,
(MedMira) (TSXV: MIR), a developer of rapid diagnostic
technology and solutions, announced today it has been invited
to participate in an exclusive conference taking place June
19-21, 2012, in Norway focused on both military and civilian
pre-hospital trauma management. The Remote Damage
Control Resuscitation (RDCR) Conference is organized by The
Norwegian Naval Special Operation Commando and the Norwegian
Air Ambulance Foundation. This three day symposium
brings together leading military and civilian medical
professionals and researchers in the field to share best
practices on pre-hospital trauma and life-threatening
haemorrhage management.
"This is the first year we have invited both civilian
and military speakers. We recognize that military and
civilian pre-hospital trauma management differs in many ways,
but there are probably more issues that bring us together
than pull us apart. We therefore want both civilian and
military perspectives to be presented," said Dr. Geir
Strandenes, Senior Medical Officer with the Norwegian Naval
Special Operation Commando, a leading researcher in
pre-hospital whole blood transfusion, and the principal
investigator of the Blood Far Forward research program.
RDCR involves the assessment and treatment of individuals
severely wounded in the field, either in a combat situation
or a civilian disaster, where evacuation to a hospital is
only possible following stabilization by individuals trained
in acute trauma care. In far forward settings there are
no traditional laboratory screening mechanisms accessible to
screen donated blood and previously collected donor blood is
not readily available. It is here that advanced
healthcare tools like MedMira rapid tests become a critical
piece of the RDCR method, where the use of fresh whole blood
products may be the only lifesaving option prior to
evacuation.
"Connecting with this world class group of medical,
scientific and research professionals is an excellent
opportunity to further illustrate the unique features of
MedMira's advanced rapid diagnostic technology and the
benefits it can bring to both combat casualty care and
civilian disaster preparedness," said Hermes Chan, CEO,
MedMira Inc. "Our ongoing work with the U.S. Army and
the Canadian Armed Forces clearly demonstrates that MedMira
rapid diagnostics can play a critical role in the treatment
of individuals critically wounded in combat. The
relationships we have built within these organizations have
led us to this opportunity in Norway and we look forward to
further collaboration with Dr. Strandenes and his
colleagues."
To learn more about the RDCR Conference visit www.wholebloodresearch.com.
About MedMira
MedMira is a leading developer and manufacturer of
flow-through rapid diagnostics and technologies. The
Company's tests provide hospitals, labs, clinics and
individuals with reliable, rapid diagnosis for diseases such
as HIV and hepatitis B and C in just three minutes. The
company's tests are sold under the Reveal®, Multiplo™ and
Miriad brands in global markets. MedMira's rapid flow-through
HIV test is the only one in the world to achieve regulatory
approvals in Canada, the United States, China and the
European Union. MedMira's corporate offices and manufacturing
facilities are located in Halifax, Nova Scotia, Canada. For
more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements,
including statements relating to growth in the Company's
business, earnings and profitability, and trends in demand
for the Company's products, which involve risk and
uncertainties and reflect the Company's current expectation
regarding future events including statements regarding
possible future growth and new business opportunities.
Actual events could materially differ from those projected
herein and depend on a number of factors including, but not
limited to, changing market conditions, successful and timely
completion of clinical studies, uncertainties related to the
regulatory approval process, establishment of corporate
alliances and other risks detailed from time to time in the
company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
MedMira Contact:
Andrea Young, Corporate Communications
Tel: 902-450-1588
Email: ayoung@medmira.com
distributed by
|
|
Recommend :
